Seeking Alpha
10 May 2026, 12:45 UTC · 19w ago
Verdict
Source says Downgrade. We score ZTS −0.80 across four claims.
Score confirms the headline.
Downgrade
Rating stated in the headline
−0.80strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Zoetis experienced an 11% year-over-year decline in US companion animal sales in Q1.
More negative than 99% of claims this week
Generic competition is eroding sales of key legacy drugs Convenia and Cerenia.
Continue reading
5 related stories
More negative than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
Structural headwinds from patent expirations outweigh cyclical pressures for Zoetis in the near term.
More negative than 98% of claims this week
International and livestock segment growth partially offset the US companion animal sales decline.
More positive than 77% of claims this week
Which stocks this story touches
More negative than 86% of ticker scores this week
The company is facing intensified sales declines in the US due to generic competition and patent expirations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
5h ago
−12.0%
Price agrees with the score
$72.89 vs $82.83 close before publication (May 8) · not market-adjusted
ZTS chart →
